Investment Thesis
Prestige Consumer Healthcare demonstrates strong operational fundamentals with 28.4% operating margins, excellent liquidity (3.57x current ratio), and robust free cash flow generation ($246.4M). However, the 2671% revenue surge coupled with 11.3% net income decline and 8.9% EPS decline signals poor acquisition quality or severe integration challenges that undermine earnings durability.
Strengths
- Exceptional operating margin (28.4%) and net margin (17.5%) with strong FCF generation ($246.4M, 22.6% FCF margin)
- Fortress-like balance sheet: 3.57x current ratio, 171.9x interest coverage, and moderate 0.53x debt/equity leverage
- Established pharma/OTC consumer healthcare business model with stable, recurring revenue characteristics
Risks
- Net income declining 11.3% YoY despite extraordinary 2671% revenue growth indicates poor acquisition accretion or massive integration costs eroding profitability
- EPS down 8.9% despite revenue surge reflects shareholder dilution and rising cost structure threatening earnings sustainability
- Critically low cash position ($63.9M) against $994M debt creates refinancing vulnerability if operating cash flow deteriorates
Key Metrics to Watch
- Normalized net income and EPS trajectory post-acquisition - must show stabilization and growth to validate deal quality
- Operating cash flow sustainability and free cash flow generation - any decline below $200M annually signals distress
- Debt reduction progress and cash position growth - critical to reduce leverage given liquidity constraints
Financial Metrics
Revenue
1.1B
Net Income
190.3M
EPS (Diluted)
$3.91
Free Cash Flow
246.4M
Total Assets
3.5B
Cash
63.9M
Profitability Ratios
Gross Margin
54.7%
Operating Margin
28.4%
Net Margin
17.5%
ROE
10.1%
ROA
5.4%
FCF Margin
22.6%
Balance Sheet & Liquidity
Current Ratio
3.57x
Quick Ratio
2.25x
Debt/Equity
0.53x
Debt/Assets
46.0%
Interest Coverage
171.89x
Long-term Debt
994.0M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T09:57:46.667026 |
Data as of: 2026-03-31 |
Powered by Claude AI